The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter 
Professionals >> Visit The Body PROThe Body en Espanol
Ask the Experts About

Choosing Your MedsChoosing Your Meds
Rollover images to visit our other forums!
  • Email Email
  • Glossary Glossary

Follow up to 14th Oct Question
Oct 14, 2006

Hi Dr Young,

Thanks for all the hard work from you and your colleagues. In a recent question about seroconversion timing you said

"a recent large study of seroconverters suggests that a significant number of patients progress to CD4s less than 350 in less than 2 years from initial infection."

As this is exactly what has happened to me I would be grateful if I could read more about this study to help understand my own situation. Please could you direct me to where I could find it?

Thanks for everything

Response from Dr. Young

Thanks for your follow up question.

The data that I referred to is from the NIH's Acute Infection and Early Disease Research Program (AIEDRP), in a presentation by Dr. Susan Little (and Dr. Martin Markowitz) at this year's ICAAC meeting.

These data have not yet been fully reviewed nor published, but represent one of the most comprehesively studied group of recently infected patients in the world. Perhaps a query to Dr. Little at TheBody's forums may get a direct reply.

Best, BY

Which Boosted PI
what immediate feelings will be noticed taking atripla

  • Email Email
  • Glossary Glossary



This forum is designed for educational purposes only, and experts are not rendering medical, mental health, legal or other professional advice or services. If you have or suspect you may have a medical, mental health, legal or other problem that requires advice, consult your own caregiver, attorney or other qualified professional.

Experts appearing on this page are independent and are solely responsible for editing and fact-checking their material. Neither nor any advertiser is the publisher or speaker of posted visitors' questions or the experts' material.

Review our complete terms of use and copyright notice.

Powered by ExpertViewpoint